BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 28521303)

  • 1. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
    Satelli A; Batth I; Brownlee Z; Mitra A; Zhou S; Noh H; Rojas CR; Li H; Meng QH; Li S
    Oncotarget; 2017 Jul; 8(30):49329-49337. PubMed ID: 28521303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
    Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
    BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer.
    Li H; Zhu YZ; Xu L; Han T; Luan J; Li X; Liu Y; Wang Z; Liu Q; Kong X; Zou C; Su L; Hou Y; Chen X; Chen L; Wang R; Xu Z; Zhao M
    J Exp Clin Cancer Res; 2024 Apr; 43(1):129. PubMed ID: 38685125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.
    Satelli A; Mitra A; Brownlee Z; Xia X; Bellister S; Overman MJ; Kopetz S; Ellis LM; Meng QH; Li S
    Clin Cancer Res; 2015 Feb; 21(4):899-906. PubMed ID: 25516888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
    Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
    J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.
    Batth IS; Dao L; Satelli A; Mitra A; Yi S; Noh H; Li H; Brownlee Z; Zhou S; Bond J; Wang J; Gill J; Sholler GS; Li S
    Int J Cancer; 2020 Dec; 147(12):3550-3559. PubMed ID: 32506485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
    Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
    Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
    Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
    Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
    Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
    J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.
    Markou A; Lazaridou M; Paraskevopoulos P; Chen S; Świerczewska M; Budna J; Kuske A; Gorges TM; Joosse SA; Kroneis T; Zabel M; Sedlmayr P; Alix-Panabières C; Pantel K; Lianidou ES
    Clin Chem; 2018 Feb; 64(2):297-306. PubMed ID: 29122836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
    Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
    Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.